CCL17 and Alzheimer disease: Although our study did not include biomarker analyses, ongoing research into the molecular underpinnings of AD suggests that certain serum cytokines and chemokines, such as TARC/CCL17 and PARC/CCL18, may serve as useful indicators of treatment response [19,20].